A phase IIb randomized, double blind, comparative study to assess the efficacy, safety, tolerability and inhibition of ovulation of two continuous regimens of oral daily 5 mg or 10 mg of ulipristal acetate (UPA), versus a dose of 5.0mg UPA for 24/4 days
Latest Information Update: 19 Sep 2014
At a glance
- Drugs Ulipristal (Primary)
- Indications Pregnancy
- Focus Pharmacodynamics
- Sponsors HRA Pharma
- 19 Sep 2014 Status changed from not stated to recruiting.
- 28 Jan 2014 New trial record